These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

931 related articles for article (PubMed ID: 23993733)

  • 21. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
    Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O; Mach N; Rothschild SI; Li Q; Stahel RA; Zippelius A; Cathomas R; Früh M; Betticher DC; Peters S; Rauch D; Feilchenfeldt J; Bubendorf L; Savic S; Jaggi R; Leibundgut EO; Largiadèr C; Brutsche M; Pilop C; Stalder L; Pless M; Ochsenbein AF;
    Clin Lung Cancer; 2015 Sep; 16(5):358-65. PubMed ID: 25843489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).
    Hata A; Katakami N; Fujita S; Nanjo S; Takeshita J; Tanaka K; Kaneda T; Nishiyama A; Nishimura T; Nakagawa A; Otsuka K; Morita S; Urata Y; Negoro S
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1267-72. PubMed ID: 25925001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.
    Kim YH; Nishimura T; Ozasa H; Nagai H; Sakamori Y; Iwata T; Sunadome H; Nishimura T; Mishima M
    Chemotherapy; 2013; 59(6):414-9. PubMed ID: 25034625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.
    Minami S; Kijima T; Takahashi R; Kida H; Nakatani T; Hamaguchi M; Takeuchi Y; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
    BMC Cancer; 2012 Jul; 12():296. PubMed ID: 22809298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
    Clément-Duchêne C; Natale RB; Jahan T; Krupitskaya Y; Osarogiagbon R; Sanborn RE; Bernstein ED; Dudek AZ; Latz JE; Shi P; Wakelee HA
    Lung Cancer; 2012 Oct; 78(1):57-62. PubMed ID: 22809813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
    Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
    Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
    Heigener DF; Deppermann KM; Pawel JV; Fischer JR; Kortsik C; Bohnet S; Eiff MV; Koester W; Thomas M; Schnabel PA; Reck M
    Lung Cancer; 2014 Apr; 84(1):62-6. PubMed ID: 24560332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
    Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
    Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
    Li N; Ou W; Ye X; Sun HB; Zhang L; Fang Q; Zhang SL; Wang BX; Wang SY
    Ann Surg Oncol; 2014 Jun; 21(6):2091-6. PubMed ID: 24585406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
    Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
    Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
    Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.